Datopotamab Deruxtecan

AUG 19, 2026 · PHASE 3 TRIAL

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

ClinicalTrials.gov

This is a clinical trial registry record describing an active Phase 3 study with no results posted; the planned design is sound but efficacy and safety outcomes remain unreported.

AUG 14, 2026 · PHASE 2 TRIAL

A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)

ClinicalTrials.gov

This is a recruiting Phase 2 single-arm trial with no posted results; it represents early-stage investigation of a three-drug combination for brain metastases from NSCLC.

AUG 12, 2026 · PHASE 3 TRIAL

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

ClinicalTrials.gov

This is a clinical trial registry record describing a planned Phase 3 study with no results posted; it documents design and enrollment targets only.